Blueprint MedicinesBPMC
BPMC
About: Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
Employees: 655
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
76% more call options, than puts
Call options by funds: $218M | Put options by funds: $124M
70% more repeat investments, than reductions
Existing positions increased: 139 | Existing positions reduced: 82
41% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 39
4% more funds holding
Funds holding: 302 [Q2] → 314 (+12) [Q3]
4.97% less ownership
Funds ownership: 110.2% [Q2] → 105.24% (-4.97%) [Q3]
18% less capital invested
Capital invested by funds: $7.44B [Q2] → $6.1B (-$1.34B) [Q3]
25% less funds holding in top 10
Funds holding in top 10: 8 [Q2] → 6 (-2) [Q3]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$124
8%
upside
Avg. target
$134
16%
upside
High target
$151
31%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Reni Benjamin 31% 1-year accuracy 11 / 36 met price target | 9%upside $125 | Market Outperform Reiterated | 15 Jan 2025 |
Wedbush David Nierengarten 38% 1-year accuracy 48 / 125 met price target | 8%upside $124 | Outperform Reiterated | 13 Jan 2025 |
Needham Ami Fadia 46% 1-year accuracy 77 / 166 met price target | 17%upside $135 | Buy Reiterated | 13 Jan 2025 |
Stephens & Co. Sudan Loganathan 45% 1-year accuracy 10 / 22 met price target | 22%upside $140 | Overweight Reiterated | 2 Jan 2025 |
HC Wainwright & Co. Andrew Fein 35% 1-year accuracy 120 / 340 met price target | 17%upside $135 | Buy Reiterated | 15 Nov 2024 |
Financial journalist opinion
Based on 4 articles about BPMC published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy
BPMC stock rallies 18% on the company's optimistic 2025 outlook encompassing Ayvakit sales growth and pipeline progress.
Positive
Zacks Investment Research
1 week ago
5 Biotech Stocks Worth Adding to Your Portfolio in 2025
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid pipeline progress position INCY, BMRN, EXEL, HALO and BPMC well in this volatile sector.
Positive
Zacks Investment Research
1 week ago
Blueprint Medicines (BPMC) Stock Jumps 18.2%: Will It Continue to Soar?
Blueprint Medicines (BPMC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neutral
PRNewsWire
2 weeks ago
Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth
-- Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritinib) launch and evolving SM prevalence estimates -- -- Expect to achieve $2 billion in AYVAKIT revenue by 2030 -- -- BLU-808 demonstrates wide therapeutic window with rapid, robust and sustained tryptase reductions exceeding 80% in Phase 1 healthy volunteer study -- -- Kate Haviland, CEO, to present at J.P. Morgan conference on Monday, January 13 at 9:00 a.m.
Neutral
PRNewsWire
1 month ago
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2025 outlook at the 43rd Annual J.P.
Neutral
PRNewsWire
1 month ago
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
-- ASH data reinforce survival benefits of front-line AYVAKIT® (avapritinib) use in patients with advanced SM -- -- Bone density analyses reported in patients with advanced SM underscore disease-modifying effects of AYVAKIT -- CAMBRIDGE, Mass. , Dec. 7, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations that continue to demonstrate the long-term clinical benefits of AYVAKIT® (avapritinib) in advanced systemic mastocytosis (advanced SM), and reflect the company's ongoing partnership with the SM community to redefine the future of patient care – from improving diagnostic rates to raising the bar on treatment outcomes.
Positive
Zacks Investment Research
1 month ago
Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue?
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?
Positive
Seeking Alpha
2 months ago
Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs
Blueprint Medicines' core revenue driver, AYVAKIT, has gained traction in systemic mastocytosis and gastrointestinal stromal tumors, reflecting strong market adoption. The recent AYVAKIT expansion into Germany and the potential for further indication of growth underpin Blueprint's valuation and future revenue projections. Blueprint's investigational pipeline, including drugs like BLU-222 and elenestinib, targets various cancers and mast cell disorders, enhancing long-term growth potential.
Positive
Benzinga
2 months ago
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
JP Morgan initiated coverage on Blueprint Medicines Corporation BPMC, a biotech company focused on modulating immune mast cells.
Positive
Zacks Investment Research
2 months ago
BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up
Blueprint stock gains from better-than-expected third-quarter results, driven by robust Ayvakit sales growth. The company raises revenue guidance for 2024.
Charts implemented using Lightweight Charts™